Additionally, miR-379-5p, which is downregulated in the bone marrow microenvironment, was found to inhibit AKR1C3, suggesting a novel miR-379-5p/AKR1C3/ERK signaling axis in imatinib resistance in CML (Pan et al., 2021). The gene discussed is AKR1C3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.